温馨提示：本站仅提供公开网络链接索引服务，不存储、不篡改任何第三方内容，所有内容版权归原作者所有
AI智能索引来源：http://www.msd.com/research/discovery-development
点击访问原文链接

Discovery & development - MSD

进入原网站 导航首页
Discovery & development - MSD Skip to content

Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy MSD Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics and compliance Diversity and inclusion Policies and positions Suppliers Suppliers overview Supplier registration Supplier help for Ariba Research Research overview Areas of focus Oncology Vaccines Infectious diseases Cardiovascular disease Immunology Neuroscience Ophthalmology Areas of innovation Data science and artificial intelligence Green and sustainable science Our therapeutic modalities Translational medicine Pipeline Business development and licensing Clinical Trials Clinical trials overview Diversity in clinical trials R&D locations How we invent Meet our scientists Publications Safety data sheets (SDS) Product patents Patients Patients overview Play an active role in your health care Fighting counterfeit medicine Media Media overview News releases Company statements Company fact sheet Investors Investors overview Events and presentations Stock information Careers Who we are Learn more Contact us What can we help you find? Search for: Research > Discovery & development How we invent Drug discovery and development is a complex and lengthy process. It requires creativity, tenacity and agility and the expertise of thousands of scientists working diligently toward our goal to save and improve lives around the world.

Drug discovery and development

We’re focused on transforming novel science into groundbreaking medicines and vaccines for patients. Our teams of scientists bring together diverse expertise and backgrounds, combined with cutting-edge technologies and tools, to help discover the next scientific breakthrough for patients.

Drug discovery: From hit to lead

MSD scientists explain how new technologies can accelerate the drug discovery process as we use the power of leading-edge science to save and improve lives. Learn more.

Analytical R&D: Partners in problem solving

Our talented scientists in our analytical research & development team are integrating state-of-the-art physical, analytical and bioanalytical solutions, and applying innovative technologies, to advance our company’s pipeline.

Formulation development: Putting the patient first

Our formulation development team explains how leading with a patient-centric approach helps advance our understanding of formulation design, material science and engineering to improve the patient experience.

Serving patients worldwide: Clinical supply & manufacturing

Our clinical supply and pharmaceutical operations teams explain the importance of staying current with trends and advancing technology for optimal clinical trials and patient outcomes.

From lab to patient: explore the journey of a molecule

Drug discovery and development involves dedication and commitment from a wide range of people — from scientists, data analysts and clinical trial volunteers to manufacturing, regulatory, development, marketing and commercial teams, among many others.

Resize icon Close icon Previous Next Previous Next Discovery is the process of exploring new and unique molecules, compounds and biologics that may have the potential to treat or prevent disease. We consider variables such as disease prevalence, unmet medical needs and current treatment options when identifying a preclinical candidate (PCC). It takes about 10 years for a new product to reach the marketplace after the initial discovery. During this phase, the active pharmaceutical ingredient is produced to create the material that will be supplied for the clinical studies. 1 in every 5,000 compounds that enter discovery and progress to preclinical development actually become an approved drug. Clinical studies determine the safety and efficacy of our products by gathering evidence through testing and analysis in trial volunteers — first in healthy volunteers, then in those with the disease. Once we have sufficient safety and efficacy data, we file an application with the information we know about the product — including study data, analyses and reports — with a regulatory agency for approval. Less than 12% of investigational medicines that enter clinical testing make it to approval. Manufacturing is the process of industrial-scale production, packaging and distribution of our medicines and vaccines. The process varies from product to product but is always in full compliance with all regulations and Good Manufacturing Practices (GMPs, also referred to as "cGMPs" or "current GMPs") to ensure a compliant, reliable supply for our patients. GMP regulations outline the minimum quality standards for manufacturing and vary by country. Each country has its own agency to monitor meeting the regulations and requirements. Once a product is approved and manufactured, we promote it — through education and awareness campaigns — to customers, including physicians, health care providers, pharmacies, patient populations, wholesalers and governments. With a customer- and data-focused approach, we develop a brand strategy to create a unique impression for each product. Marketing teams are key to creating the campaigns to educate stakeholders (customers) about the efficacy and safety of our products to ensure appropriate use. Post-marketing begins when the medicine or vaccine is released to the market. It includes activities to monitor and evaluate the product for safety and efficacy in a real-world setting. Companies monitor approved medicines for as long as they are on the market. This meets regulatory reporting requirements, provides internal reporting for ongoing analyses and supplies data to support the safety of the product.

Download the Infographic

Clinical trials Clinical trials are a key part of the drug development process, testing the safety and effectiveness of medicines and vaccines in development and exploring how different people’s bodies respond to them. Ensuring our data represents varied backgrounds advances science and improves lives by reflecting the true diversity of the populations we aim to serve.

Learn more about clinical trials × Advance your R&D career with us We’re looking for world-class scientists to join our R&D team who are passionate about making a difference for patients.

Explore the possibilities Related links Pipeline We're focused on discovering new solutions for today and the future. Where our science happens Our research and development starts with the capabilities and expertise at our facilities, but we're open to collaboration anywhere the science leads us. Meet our scientists Meet our research leaders who are dedicated to pushing scientific boundaries. Connect with us on social For patients and health care professionals MSD Manuals
Medical information source covering thousands of topics in all fields of medicine Clinical trials
Learn about our clinical trials and find available studies Sustainability Impact Report
Reporting on our commitment to operating responsibly to benefit society MSD for Mothers
An initiative to create a world where no woman has to die giving life About MSD MSD Animal Health
The global animal health business unit of MSD Contact Us
If you have a question or need more information about us, find out who you should contact. Forward-looking statementCookie policyCookie PreferencesPrivacyTerms of useAccessibilitySitemap Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept

智能索引记录